Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:ENTA NASDAQ:GLSI NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.46+1.2%$2.06$1.27▼$4.75$91.32M1.65218,276 shs223,434 shsENTAEnanta Pharmaceuticals$11.90+3.4%$13.44$6.43▼$17.15$334.69M0.97195,780 shs190,272 shsGLSIGreenwich LifeSciences$24.06+4.5%$24.84$7.78▼$34.10$338.04M1.4145,870 shs94,400 shsRGNXREGENXBIO$6.66+6.1%$7.98$5.45▼$16.19$324.66M1.041.67 million shs903,377 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+7.05%+2.97%+10.45%+73.57%-39.55%ENTAEnanta Pharmaceuticals-1.62%-1.88%-20.78%-9.37%+44.78%GLSIGreenwich LifeSciences+4.16%-2.70%-6.80%-13.87%+139.15%RGNXREGENXBIO+2.45%-8.72%-38.67%-26.72%-38.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.46+1.2%$2.06$1.27▼$4.75$91.32M1.65218,276 shs223,434 shsENTAEnanta Pharmaceuticals$11.90+3.4%$13.44$6.43▼$17.15$334.69M0.97195,780 shs190,272 shsGLSIGreenwich LifeSciences$24.06+4.5%$24.84$7.78▼$34.10$338.04M1.4145,870 shs94,400 shsRGNXREGENXBIO$6.66+6.1%$7.98$5.45▼$16.19$324.66M1.041.67 million shs903,377 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+7.05%+2.97%+10.45%+73.57%-39.55%ENTAEnanta Pharmaceuticals-1.62%-1.88%-20.78%-9.37%+44.78%GLSIGreenwich LifeSciences+4.16%-2.70%-6.80%-13.87%+139.15%RGNXREGENXBIO+2.45%-8.72%-38.67%-26.72%-38.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.25Hold$2.7511.79% UpsideENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2970.47% UpsideGLSIGreenwich LifeSciences 2.33Hold$47.5097.42% UpsideRGNXREGENXBIO 2.73Moderate Buy$23.55253.54% UpsideCurrent Analyst Ratings BreakdownLatest BTMD, ENTA, RGNX, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026RGNXREGENXBIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/5/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $26.005/28/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/15/2026GLSIGreenwich LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026RGNXREGENXBIO Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.005/15/2026RGNXREGENXBIO BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$37.00 ➝ $12.005/15/2026RGNXREGENXBIO Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $14.005/13/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)4/20/2026ENTAEnanta Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.003/26/2026ENTAEnanta Pharmaceuticals Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$192.22M0.48$0.59 per share4.19($1.40) per share-1.76ENTAEnanta Pharmaceuticals$65.32M5.30N/AN/A$3.03 per share3.93GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.03 per shareN/ARGNXREGENXBIO$170.44M2.02N/AN/A$2.03 per share3.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$27.05M$0.445.594.64N/A8.29%-25.72%15.12%8/5/2026 (Estimated)ENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)GLSIGreenwich LifeSciences-$19.36M-$1.57N/AN/AN/AN/A-941.15%-368.53%8/13/2026 (Estimated)RGNXREGENXBIO-$193.88M-$5.60N/AN/AN/A-330.23%-232.50%-61.02%8/6/2026 (Estimated)Latest BTMD, ENTA, RGNX, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026RGNXREGENXBIO-$1.36-$1.72-$0.36-$1.72$25.84 million$6.39 million5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/6/2026Q1 2026BTMDbiote$0.09$0.06-$0.03$0.06$46.02 million$44.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.290.58ENTAEnanta PharmaceuticalsN/A3.843.84GLSIGreenwich LifeSciencesN/A2.012.01RGNXREGENXBION/A2.622.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%ENTAEnanta Pharmaceuticals94.99%GLSIGreenwich LifeSciences4.16%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipBTMDbiote32.40%ENTAEnanta Pharmaceuticals11.48%GLSIGreenwich LifeSciences51.47%RGNXREGENXBIO14.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19437.58 million25.41 millionNot OptionableENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableGLSIGreenwich LifeSciences314.68 million7.12 millionNot OptionableRGNXREGENXBIO37051.70 million44.35 millionOptionableBTMD, ENTA, RGNX, and GLSI HeadlinesRecent News About These CompaniesWhat is HC Wainwright's Forecast for REGENXBIO Q3 Earnings?June 8, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)June 6, 2026 | theglobeandmail.comHow The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst CommentaryJune 2, 2026 | finance.yahoo.comREGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 22, 2026 | seekingalpha.comREGENXBIO to Participate in Upcoming Investor ConferencesMay 18, 2026 | prnewswire.comStockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy CandidateMay 18, 2026 | genengnews.comGRegenxbio (RGNX) Q1 2026 Earnings TranscriptMay 18, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)May 17, 2026 | theglobeandmail.comRegenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD ResultsMay 17, 2026 | seekingalpha.comBank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock PriceMay 15, 2026 | marketbeat.comRegenxbio: Q1 Earnings SnapshotMay 15, 2026 | stamfordadvocate.comSRGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial successMay 15, 2026 | msn.comREGENXBIO Inc. (RGNX) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comRegenxbio's muscle disorder therapy meets main goal in late-stage studyMay 14, 2026 | msn.comRegenxbio slides after late-stage trial data for Duchenne therapyMay 14, 2026 | seekingalpha.comRegenxbio Shares Rise After Positive Duchenne Trial ResultsMay 14, 2026 | finance.yahoo.comRegenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ...May 14, 2026 | finance.yahoo.comREGENXBIO (NASDAQ:RGNX) Releases Earnings Results, Misses Estimates By $0.38 EPSMay 14, 2026 | marketbeat.comREGENXBIO Advances Duchenne Gene Therapy Toward Accelerated ApprovalMay 14, 2026 | benzinga.comRegenxbio (RGNX) Reports Q1 Loss, Lags Revenue EstimatesMay 14, 2026 | zacks.comInsider Selling: REGENXBIO (NASDAQ:RGNX) Insider Sells 15,309 Shares of StockMay 14, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 2026Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameBy Leo Miller | June 1, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Intel Is the Market's Most Mispriced AI HedgeBy Jeffrey Neal Johnson | June 10, 2026The Pentagon's AI Pivot Supercharges Defense StocksBy Jeffrey Neal Johnson | May 19, 2026BTMD, ENTA, RGNX, and GLSI Company Descriptionsbiote NASDAQ:BTMD$2.46 +0.03 (+1.23%) Closing price 04:00 PM EasternExtended Trading$2.46 0.00 (0.00%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Enanta Pharmaceuticals NASDAQ:ENTA$11.90 +0.39 (+3.39%) Closing price 04:00 PM EasternExtended Trading$11.92 +0.02 (+0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Greenwich LifeSciences NASDAQ:GLSI$24.06 +1.03 (+4.47%) Closing price 04:00 PM EasternExtended Trading$24.14 +0.08 (+0.33%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.REGENXBIO NASDAQ:RGNX$6.66 +0.38 (+6.05%) Closing price 04:00 PM EasternExtended Trading$6.57 -0.09 (-1.35%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
